Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 539.6 g/mol |
---|---|
Molecular Formula | C31H33N5O4 |
XLogP3 | 3.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 8 |
Exact Mass | 539.25325455 g/mol |
Monoisotopic Mass | 539.25325455 g/mol |
Topological Polar Surface Area | 94.2 A^2 |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 947 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Ofev |
Drug Label | OFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin... |
Active Ingredient | Nintedanib |
Dosage Form | Capsule |
Route | Oral |
Strength | 150mg; 100mg |
Market Status | Prescription |
Company | Boehringer Ingelheim |
2 of 2 | |
---|---|
Drug Name | Ofev |
Drug Label | OFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin... |
Active Ingredient | Nintedanib |
Dosage Form | Capsule |
Route | Oral |
Strength | 150mg; 100mg |
Market Status | Prescription |
Company | Boehringer Ingelheim |
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-03-26
Pay. Date : 2018-12-20
DMF Number : 33361
Submission : 2019-01-02
Status : Active
Type : II
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2022-01-12
Registration Number : 163-23-ND
Manufacturer Name : Fermion Oy
Manufacturer Address : Lääketehtaantie 2, Oulu, FI-90660, Finland
Available Reg Filing : ASMF |
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-04-27
Pay. Date : 2018-03-30
DMF Number : 32511
Submission : 2018-03-29
Status : Active
Type : II
IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-01-19
Pay. Date : 2022-12-20
DMF Number : 37872
Submission : 2022-12-29
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-05-08
Pay. Date : 2023-03-28
DMF Number : 37986
Submission : 2023-03-01
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MNKD-201
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2024
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrosis
Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Brand Name : MNKD-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 04, 2024
Details:
AP02 (nintedanib) is a multiple tyrosine kinase inhibitor, being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: AP02
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2024
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avalyn Initiates Phase 1b Study for AP02, Novel Inhaled Nintedanib
Details : AP02 (nintedanib) is a multiple tyrosine kinase inhibitor, being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Brand Name : AP02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 12, 2024
Details:
The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MNKD-201
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MannKind Proceeds with Phase 1 Nintedanib Dpi Study for Pulmonary Fibrotic Diseases
Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Brand Name : MNKD-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 30, 2024
Details:
OFEV (nintedanib) is an investigational drug in development for fibrosing interstitial lung disease. It inhibits profibrotic mediators including platelet-derived growth factor, TGF-β as well as VEGF, reducing fibroblast activity.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
U.S. FDA Accepts Supplemental New Drug Application for OFEV® (nintedanib) for Children and Adoles...
Details : OFEV (nintedanib) is an investigational drug in development for fibrosing interstitial lung disease. It inhibits profibrotic mediators including platelet-derived growth factor, TGF-β as well as VEGF, reducing fibroblast activity.
Brand Name : Ofev
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 25, 2023
Details:
AP02 (nintedanib) is an investigational drug in development for pulmonary fibrosis. It inhibits profibrotic mediators including platelet-derived growth factor, fibroblast growth factor and transforming growth factor (TGF)-β as well as VEGF, reducing fibroblast activity.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: AP02
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AP02 (nintedanib) is an investigational drug in development for pulmonary fibrosis. It inhibits profibrotic mediators including platelet-derived growth factor, fibroblast growth factor and transforming growth factor (TGF)-β as well as VEGF, reducing fib...
Brand Name : AP02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2023
Details:
The InPedILD results showed that the weight-based dosing regimen of Ofev (nintedanib) in children and adolescents with fibrosing ILD resulted in comparable exposure to that observed in adult patients with fibrosing ILD.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The InPedILD results showed that the weight-based dosing regimen of Ofev (nintedanib) in children and adolescents with fibrosing ILD resulted in comparable exposure to that observed in adult patients with fibrosing ILD.
Brand Name : Ofev
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 05, 2022
Details:
No significant drug-drug interaction (DDI) seen with BLD-0409 (cudetaxestat) in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF).
Lead Product(s): Cudetaxestat,Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLD-0409
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Lead Product(s) : Cudetaxestat,Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : No significant drug-drug interaction (DDI) seen with BLD-0409 (cudetaxestat) in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF).
Brand Name : BLD-0409
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2022
Details:
In an analysis of SENSCIS-ON, the safety profile of Ofev in participants who continued therapy for an additional 52 weeks was consistent with that observed during the SENSCIS trial.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Immunology Brand Name: Ofev
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2021
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In an analysis of SENSCIS-ON, the safety profile of Ofev in participants who continued therapy for an additional 52 weeks was consistent with that observed during the SENSCIS trial.
Brand Name : Ofev
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 14, 2021
Details:
OFEV® is the first treatment available in Canada for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD), which affects patients across more than 200 rare lung disorders.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: OFEV
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OFEV® is the first treatment available in Canada for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD), which affects patients across more than 200 rare lung disorders.
Brand Name : OFEV
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 04, 2021
Details:
New study will assess the potential impact of nintedanib in patients developing pulmonary fibrosis following acute lung injury from COVID-19 infection. Research collaboration will lead to insights about pulmonary fibrosis in the growing COVID-19 patient population.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Icahn School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 19, 2020
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Icahn School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : New study will assess the potential impact of nintedanib in patients developing pulmonary fibrosis following acute lung injury from COVID-19 infection. Research collaboration will lead to insights about pulmonary fibrosis in the growing COVID-19 patient ...
Brand Name : Ofev
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 19, 2020
methyl 1-acetyl-3-(methoxy(phenyl)methylene)-2-oxo...
CAS Number : 1168152-07-5
End Use API : Nintedanib Esylate
About The Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services co...
N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-...
CAS Number : 262368-30-9
End Use API : Nintedanib Esylate
About The Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services co...
Methyl-1-(Chloro Acetyl)-2- Oxoindoline-6-Carboxyl...
CAS Number : CAS-1160293-25-3
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
CAS Number : CAS-14192-26-8
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
1,3-Dimethyl 2-[4- (Methoxycarbonyl)-2- Nitropheny...
CAS Number : CAS-1160293-27-5
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
(Z)-Methyl 1-(2-Chloroacetyl)- 3- (Methoxy (Phenyl...
CAS Number : CAS-1160293-24-2
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
Methyl 3-[Methoxy (Phenyl)Methylene]-2- Oxoindolin...
CAS Number : CAS-1160293-22-0
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
Methyl 2-Oxindoline -6-carboxylate
CAS Number : 14192-26-8
End Use API : Nintedanib Esylate
About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...
2-Chloro N-methyl N-(4-nitro-phenyl)acetamide
CAS Number : 2653-16-9
End Use API : Nintedanib Esylate
About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...
Methyl 2-oxindole-6-carboxylate
CAS Number : 14192-26-8
End Use API : Nintedanib Esylate
About The Company : Fujian South Pharmaceutical Co., Ltd. (Southern Pharmaceutical) was established in September 2001 and is located in Mingxi County, Fujian Province. After 16 ye...
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Nintedanib Esylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nintedanib Esylate, including repackagers and relabelers. The FDA regulates Nintedanib Esylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nintedanib Esylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nintedanib Esylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nintedanib Esylate supplier is an individual or a company that provides Nintedanib Esylate active pharmaceutical ingredient (API) or Nintedanib Esylate finished formulations upon request. The Nintedanib Esylate suppliers may include Nintedanib Esylate API manufacturers, exporters, distributors and traders.
click here to find a list of Nintedanib Esylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nintedanib Esylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Nintedanib Esylate active pharmaceutical ingredient (API) in detail. Different forms of Nintedanib Esylate DMFs exist exist since differing nations have different regulations, such as Nintedanib Esylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nintedanib Esylate DMF submitted to regulatory agencies in the US is known as a USDMF. Nintedanib Esylate USDMF includes data on Nintedanib Esylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nintedanib Esylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nintedanib Esylate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nintedanib Esylate Drug Master File in Korea (Nintedanib Esylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nintedanib Esylate. The MFDS reviews the Nintedanib Esylate KDMF as part of the drug registration process and uses the information provided in the Nintedanib Esylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nintedanib Esylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nintedanib Esylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nintedanib Esylate suppliers with KDMF on PharmaCompass.
A Nintedanib Esylate written confirmation (Nintedanib Esylate WC) is an official document issued by a regulatory agency to a Nintedanib Esylate manufacturer, verifying that the manufacturing facility of a Nintedanib Esylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nintedanib Esylate APIs or Nintedanib Esylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Nintedanib Esylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Nintedanib Esylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nintedanib Esylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nintedanib Esylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nintedanib Esylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nintedanib Esylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nintedanib Esylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nintedanib Esylate suppliers with NDC on PharmaCompass.
Nintedanib Esylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nintedanib Esylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nintedanib Esylate GMP manufacturer or Nintedanib Esylate GMP API supplier for your needs.
A Nintedanib Esylate CoA (Certificate of Analysis) is a formal document that attests to Nintedanib Esylate's compliance with Nintedanib Esylate specifications and serves as a tool for batch-level quality control.
Nintedanib Esylate CoA mostly includes findings from lab analyses of a specific batch. For each Nintedanib Esylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nintedanib Esylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Nintedanib Esylate EP), Nintedanib Esylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nintedanib Esylate USP).
LOOKING FOR A SUPPLIER?